BIOV:CA:CNSX-BioVaxys Technology Corp (CAD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.06

Change

0.00 (0.00)%

Market Cap

USD 0.01B

Volume

0.32M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune-educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. Its product pipeline includes Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and for platinum resistant ovarian cancer; MVP-S +1 Keytruda that is in IIb clinical trial to treat lung cancer, bladder cancer, liver cancer, DLBCL, and ovarian cancer subpopulations; BVX-0918, a haptenized tumor cell vaccine for ovarian cancer; and DPX SurMAGE, which is in phase I clinical stage to treat the MAGE protein family member A9 in human cancers. It also develops DPX-RSV that is in phase II clinical stage for Respiratory Syncytial Virus; DPX-Flu, which is in phase I clinical stage used to treat multiple strains of influenza; DPX-Neo, which is in phase I trial used for evaluating UConn Health's proprietary neoepitopes; DPX-E7 to evaluate changes in CD8+ T cells in peripheral blood and tumor tissue and evaluate the safety in HLA-A2positive patients; and DPX-rPA anthrax vaccine. In addition, the company operates T-Cell Antigen Discovery Program. It has agreement with AP Visionaries, Inc. to develop a proprietary DPX" formulation to address the urgent need for a therapy to treat or alleviate the potentially life-threatening risk of certain food allergies, namely those triggered by exposure to peanut/tree nuts or eggs. BioVaxys Technology Corp. is headquartered in Etobicoke, Canada.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
DRUG:CA Bright Minds Biosciences Inc

+0.25 (+0.43%)

USD 0.38B
METX:CA METX

+0.05 (+1.25%)

USD 0.10B
GLAB:CA Gemina Laboratories Ltd

-0.08 (-10.26%)

USD 0.05B
ACOG:CA Alpha Cognition Inc.

N/A

USD 0.05B
DTC:CA Defence Therapeutics Inc

-0.03 (-4.41%)

USD 0.03B
MDMA:CA Pharmala Biotech Holdings Inc.

+0.01 (+1.69%)

USD 0.03B
DOSE:CA Rapid Dose Therapeutics Corp

N/A

USD 0.03B
PHRM:CA PharmaTher Holdings Ltd

-0.01 (-4.55%)

USD 0.02B
TELI:CA Telescope Innovations Corp.

N/A

USD 0.02B
BETR:CA BetterLife Pharma Inc

+0.01 (+9.52%)

USD 0.01B

ETFs Containing BIOV:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 20.00% 53% F 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.00% 53% F 71% C-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 1.62% 72% C 64% D
Dividend Return 1.62% 72% C 64% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 93.47% 25% F 25% F
Risk Adjusted Return 1.73% 69% C- 63% D
Market Capitalization 0.01B 72% C 81% B-

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.